IRIS Accounts Production v25.1.0.734 06071342 director 1.3.24 28.2.25 28.2.25 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh060713422024-02-29060713422025-02-28060713422024-03-012025-02-28060713422023-02-23060713422023-02-242024-02-29060713422024-02-2906071342ns14:PoundSterling2024-03-012025-02-2806071342ns10:Director12024-03-012025-02-2806071342ns10:PrivateLimitedCompanyLtd2024-03-012025-02-2806071342ns10:SmallEntities2024-03-012025-02-2806071342ns10:AuditExempt-NoAccountantsReport2024-03-012025-02-2806071342ns10:SmallCompaniesRegimeForDirectorsReport2024-03-012025-02-2806071342ns10:SmallCompaniesRegimeForAccounts2024-03-012025-02-2806071342ns10:FullAccounts2024-03-012025-02-280607134212024-03-012025-02-2806071342ns10:CompanySecretary12024-03-012025-02-2806071342ns10:RegisteredOffice2024-03-012025-02-2806071342ns5:CurrentFinancialInstruments2025-02-2806071342ns5:CurrentFinancialInstruments2024-02-2906071342ns5:ShareCapital2025-02-2806071342ns5:ShareCapital2024-02-2906071342ns5:RetainedEarningsAccumulatedLosses2025-02-2806071342ns5:RetainedEarningsAccumulatedLosses2024-02-2906071342ns5:NetGoodwill2024-03-012025-02-2806071342ns5:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2806071342ns5:PlantMachinery2024-03-012025-02-2806071342ns5:NetGoodwill2024-02-2906071342ns5:NetGoodwill2025-02-2806071342ns5:NetGoodwill2024-02-2906071342ns5:FurnitureFittings2024-02-2906071342ns5:ComputerEquipment2024-02-2906071342ns5:FurnitureFittings2024-03-012025-02-2806071342ns5:ComputerEquipment2024-03-012025-02-2806071342ns5:FurnitureFittings2025-02-2806071342ns5:ComputerEquipment2025-02-2806071342ns5:FurnitureFittings2024-02-2906071342ns5:ComputerEquipment2024-02-2906071342ns5:CostValuation2024-02-2906071342ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2806071342ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-29
REGISTERED NUMBER: 06071342















Financial Statements for the Year Ended 28 February 2025

for

Singh Pharma Limited

Singh Pharma Limited (Registered number: 06071342)






Contents of the Financial Statements
for the Year Ended 28 February 2025




Page

Company information 1

Balance sheet 2

Notes to the financial statements 3


Singh Pharma Limited

Company Information
for the Year Ended 28 February 2025







Director: G Singh





Secretary: K Singh





Registered office: 22 Sandhill Fold
Bradford
Yorkshire
BD10 8XB





Registered number: 06071342





Accountants: Sohans, Chartered Accountants
44 Bradford Street
Walsall
WS1 3QA

Singh Pharma Limited (Registered number: 06071342)

Balance Sheet
28 February 2025

28.2.25 29.2.24
Notes £    £    £    £   
Fixed assets
Intangible assets 4 500,000 500,000
Tangible assets 5 12,688 8,820
Investments 6 39,920 39,920
552,608 548,740

Current assets
Stocks 60,290 76,321
Debtors 7 695,177 705,872
Cash at bank and in hand 67,507 161,152
822,974 943,345
Creditors
Amounts falling due within one year 8 522,342 654,481
Net current assets 300,632 288,864
Total assets less current liabilities 853,240 837,604

Capital and reserves
Called up share capital 4 4
Retained earnings 853,236 837,600
Shareholders' funds 853,240 837,604

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 26 November 2025 and were signed by:



G Singh - Director


Singh Pharma Limited (Registered number: 06071342)

Notes to the Financial Statements
for the Year Ended 28 February 2025

1. Statutory information

Singh Pharma Limited is a private company, limited by shares , registered in Not specified/Other. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost and 15% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Singh Pharma Limited (Registered number: 06071342)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

3. Employees and directors

The average number of employees during the year was 11 (2024 - 11 ) .

4. Intangible fixed assets
Goodwill
£   
Cost
At 1 March 2024
and 28 February 2025 500,000
Net book value
At 28 February 2025 500,000
At 29 February 2024 500,000

5. Tangible fixed assets
Fixtures
and Computer
fittings equipment Totals
£    £    £   
Cost
At 1 March 2024 47,119 2,092 49,211
Additions - 7,748 7,748
At 28 February 2025 47,119 9,840 56,959
Depreciation
At 1 March 2024 38,299 2,092 40,391
Charge for year 1,323 2,557 3,880
At 28 February 2025 39,622 4,649 44,271
Net book value
At 28 February 2025 7,497 5,191 12,688
At 29 February 2024 8,820 - 8,820

6. Fixed asset investments
Other
investments
£   
Cost
At 1 March 2024
and 28 February 2025 39,920
Net book value
At 28 February 2025 39,920
At 29 February 2024 39,920

Singh Pharma Limited (Registered number: 06071342)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

7. Debtors: amounts falling due within one year
28.2.25 29.2.24
£    £   
Trade debtors 108,031 90,837
Prepayments 587,146 615,035
695,177 705,872

8. Creditors: amounts falling due within one year
28.2.25 29.2.24
£    £   
Bank loans and overdrafts 195,817 258,892
Trade creditors 218,493 266,597
Taxation and social security 23,586 16,048
Other creditors 84,446 112,944
522,342 654,481

9. Ultimate controlling party

The controlling party is G Singh.